The Department of Defense requires an integrated pharmacy benefits program for the Military Health System, involving the selection of pharmaceutical agents for the Uniform Formulary based on clinical and cost effectiveness. A Request for Quotation has been issued for drug classes under review, with potential awards of Uniform Formulary Blanket Purchase Agreements and Additional Discount Program Agreements. The May 2026 Pharmacy and Therapeutics Committee meeting will review newly approved drugs, including Lifyorli, Quiofic, Widaplik, and Saphnelo. A pre-quotation teleconference is scheduled for May 13, 2026. No budget amounts or performance location are specified.

The Department of War is required to establish an integrated pharmacy benefits program for the Military Health System, involving the selection of pharmaceutical agents for the Uniform Formulary based on clinical and cost effectiveness. A Request for Quotation has been issued for drug classes under review, with potential awards of Uniform Formulary Blanket Purchase Agreements and Additional Discount Program Agreements. The Pharmacy and Therapeutics Committee will review newly approved drugs in May 2026, including Lifyorli, Quiofic, Widaplik, and Saphnelo. A pre-quotation teleconference is scheduled for May 13, 2026, with details provided in the RFQ. Responses to clinical questions must be submitted via email by the deadline specified in the RFQ.